CELZ Stock Price, Creative Medical Technology Holdings Quote, Chart

Market Summary

USD4.35+0.01

Delayed

0.23%

CELZ Stock Price

View Fullscreen

CELZ RSI Chart

CELZ Valuation

Market Cap

5.9M

Price/Earnings (Trailing)

-1.11

Price/Sales (Trailing)

55.96

EV/EBITDA

0.6

Price/Free Cashflow

-1.15

CELZ Price/Sales (Trailing)

CELZ Profitability

Operating Margin

96.53%

EBT Margin

-5092.85%

Return on Equity

-57.17%

Return on Assets

-54.85%

Free Cashflow Yield

-86.68%

CELZ Fundamentals

CELZ Revenue

Revenue (TTM)

103.6K

Rev. Growth (Yr)

134.31%

Rev. Growth (Qtr)

-0.76%

CELZ Earnings

Earnings (TTM)

-5.3M

Earnings Growth (Yr)

0.99%

Earnings Growth (Qtr)

37.95%

Breaking Down CELZ Revenue

Last 30 days

-12.8%

Last 90 days

2.8%

Trailing 12 Months

-26.5%

How does CELZ drawdown profile look like?

CELZ Financial Health

Current Ratio

23.54

CELZ Investor Care

Buy Backs (1Y)

4.23%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	102.8K	92.8K	120.8K	103.6K
2021	0	132.4K	114.5K	105.3K
2020	165.3K	165.0K	164.8K	164.5K
2019	165.6K	222.4K	227.5K	165.5K
2018	34.7K	64.6K	94.5K	124.4K
2017	0	0	0	4.8K
2016	15.4K	0	0	0
2015	17.6K	17.8K	18.0K	19.8K
2014	19.0K	18.6K	18.6K	18.7K
2013	19.9K	20.2K	19.7K	19.4K
2012	19.3K	19.7K	20.3K	19.2K
2011	15.1K	16.1K	17.0K	18.0K
2010	0	0	0	14.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Creative Medical Technology Holdings

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 28, 2023	warbington timothy	bought	872	4.36	200	president & ceo
Jun 27, 2023	warbington timothy	bought	3,551	4.43875	800	president & ceo
Nov 22, 2022	warbington timothy	bought	3,897	0.389742	10,000	president & ceo
Nov 21, 2022	warbington timothy	bought	5,965	0.397667	15,000	president & ceo
Sep 27, 2022	finger michael h.	bought	1,000	0.5	2,000	-
Sep 27, 2022	warbington timothy	bought	10,000	0.5	20,000	president & ceo
Sep 22, 2022	warbington timothy	bought	6,480	0.54	12,000	president & ceo
Sep 21, 2022	warbington timothy	bought	18,337	0.611242	30,000	president & ceo
Jun 14, 2022	finger michael h.	bought	7,000	0.7	10,000	-
Jun 06, 2022	warbington timothy	bought	22,884	0.91536	25,000	president & ceo

Which funds bought or sold CELZ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	77,619	77,619	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	new	-	61,186	61,186	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	86.49	4,611	8,774	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	563	563	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	12.00	104	-%
May 14, 2024	OMERS ADMINISTRATION Corp	new	-	57,310	57,310	-%
May 13, 2024	HRT FINANCIAL LP	new	-	68,000	68,000	-%
May 13, 2024	UBS Group AG	added	194	11,159	15,963	-%
May 10, 2024	VANGUARD GROUP INC	added	0.02	10,593	91,863	-%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-	5.00	-%

Are Funds Buying or Selling CELZ?

Are funds buying CELZ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CELZ

No. of Funds

Unveiling Creative Medical Technology Holdings's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 26, 2023	markey john	-	0	SC 13G/A
May 02, 2023	markey john	5.1%	717,570	SC 13G
Feb 14, 2022	altium capital management lp	4.99%	363,000	SC 13G/A
Feb 14, 2022	l1 capital global opportunities master fund, ltd.	4.9%	327,458	SC 13G/A
Feb 14, 2022	cvi investments, inc.	4.9%	332,317	SC 13G/A
Dec 20, 2021	altium capital management lp	5.7%	363,000	SC 13G
Dec 10, 2021	cvi investments, inc.	5.2%	326,500	SC 13G
Dec 08, 2021	l1 capital global opportunities master fund, ltd.	5.1%	327,458	SC 13G

Recent SEC filings of Creative Medical Technology Holdings

View All Filings

Date Filed	Form Type	Document
May 17, 2024	PRE 14A	PRE 14A
May 17, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Mar 22, 2024	10-K	Annual Report

Peers (Alternatives to Creative Medical Technology Holdings)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Creative Medical Technology Holdings News

Latest updates

Creative Medical Technology Holdings Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	89,233	89,913	70,215	50,517	38,083	-	15,000	67,754	10,000	10,000	17,500	77,000	27,900	42,100	49,800	57,500	61,600	50,800	57,600
Cost Of Revenue	-100.0%	-	1,200	2,400	-	-	5,700	16,000	-	6,791	39,449	4,000	4,500	8,000	17,600	10,800	14,196	4,060	8,000	19,200	14,239	29,052
Gross Profit	-100.0%	-	1,800	3,600	-	-	12,900	39,000	-	8,209	28,305	6,000	5,500	9,500	59,400	17,100	27,904	-8,460	49,500	42,400	36,561	28,548
Operating Expenses	-36.7%	1,123,147	1,773,639	1,546,785	1,192,038	1,113,070	6,290,837	1,059,422	1,791,144	1,163,078	1,501,032	839,436	521,342	332,564	301,871	231,364	362,940	322,129	322,922	317,858	287,260	348,892
S&GA Expenses	-52.0%	671,484	1,398,710	531,042	859,537	771,020	899,597	805,461	1,108,428	1,130,057	1,428,011	757,235	498,321	315,793	285,100	214,886	346,168	311,037	317,636	312,572	281,974	257,269
R&D Expenses	20.9%	422,392	349,408	992,722	309,480	319,029	-	230,940	659,695	10,000	50,000	59,180	-	-	-	-	-	-	-	-	-	86,337
EBITDA Margin	0.2%	-50.93	-51.03	-94.82	-90.27	-96.92	-97.92	-44.70	-53.44	-56.80	223	-116	-91.51	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-50.00	50.00	-	-	-	-	2,402,746	1,305,273	234,338	319,354	289,210	297,803	323,223	407,544	529,188	504,254	454,542	380,086
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	38.0%	-1,041,544	-1,678,574	-1,453,952	-1,102,125	-1,051,923	-6,215,692	-982,339	-1,791,144	-1,154,869	-3,875,473	-1,843,596	-2,905,182	-38,619,998	394,851	-1,842,563	3,742,480	-5,191,950	-2,406,124	-88,233	-797,366	1,934,351
EBT Margin	0.2%	-50.93	-51.03	-94.82	-90.27	-96.92	-97.92	-64.58	-93.42	-95.17	182	-135	-100	-	-	-	-	-	-	-	-	-
Net Income	38.0%	-1,041,544	-1,678,574	-1,453,952	-1,102,125	-1,051,923	-6,215,692	-982,339	-1,791,144	-1,154,869	-3,875,473	-1,843,596	-2,905,182	-38,619,998	394,851	-1,842,563	3,742,480	-5,191,950	-2,406,124	-88,233	-797,366	1,934,351
Net Income Margin	0.2%	-50.93	-51.03	-94.82	-90.27	-96.92	-97.92	-64.58	-93.42	-95.17	182	-135	-100	-	-	-	-	-	-	-	-	-
Free Cashflow	52.7%	-896,864	-1,894,983	-1,304,523	-986,737	-3,841,642	-3,591,234	-873,303	-1,755,536	-1,576,893	-1,161,336	-390,789	-222,139	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.2%	9,620	10,715	12,514	14,127	15,229	19,186	22,468	23,434	9,734	11,268	3,132	732	872	718	425	443	469	531	330	358	578
Current Assets	-10.4%	9,205	10,271	12,044	13,735	14,814	18,747	22,006	22,949	9,226	10,737	2,578	159	275	98.00	39.00	40.00	50.00	94.00	183	205	420
Cash Equivalents	159.8%	9,007	3,467	4,507	3,990	9,516	8,321	16,969	22,864	9,147	10,724	2,378	159	275	98.00	39.00	37.00	38.00	89.00	158	204	419
Inventory	0%	7.00	7.00	8.00	10.00	10.00	10.00	16.00	21.00	14.00	11.00	-	-	-	-	-	1.00	3.00	-	-	-	-
Liabilities	5.3%	391	371	421	399	408	3,322	2,754	2,186	1,618	1,050	-	-	-	40,521	3,202	4,648	3,652	8,602	3,893	2,995	4,183
Current Liabilities	5.3%	391	371	421	399	408	3,322	397	390	380	1,050	3,495	1,447	3,314	40,521	3,202	4,648	3,652	8,602	3,893	2,995	4,183
Shareholder's Equity	-10.8%	9,229	10,344	12,092	13,729	14,822	15,865	22,071	23,044	9,354	10,218	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.8%	-60,139	-59,098	-57,419	-55,965	-54,863	-53,811	-47,596	-46,613	-44,822	-43,667	-38,803	-36,959	-34,054	-61,890	-23,270	-23,665	-21,822	-25,565	-20,373	-17,966	-17,878
Additional Paid-In Capital	0.0%	69,721	69,712	69,703	69,693	69,672	69,675	69,653	69,644	54,170	53,879	38,434	34,560	30,001	22,083	20,015	19,212	18,552	17,490	14,699	14,139	13,263
Shares Outstanding	-1.2%	1,357	1,374	1,391	1,431	1,408	1,408	1,408	1,396	652	634	245	232	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	6,633	-	-	-	6,194	-	-	-	38,245	-	-	-	1,139	-	4,632	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	52.7%	-896	-1,894	-1,304	-986	-3,841	-3,591	-873	-1,755	-1,576	-1,161	-390	-222	-441	57.00	-174	-122	-195	-252	-358	-329	-273
Share Based Compensation	0%	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	41.00	-	384	-	-	102	-	-	-	-	-	-	-
Cashflow From Investing	479.2%	6,520	1,126	1,822	-4,539	5,037	-5,057	-5,021	-	-	200	-200	-	-	-250	-	-	-	-	-	-	-
Cashflow From Financing	69.4%	-82.80	-270	-	-	-	-	12*	15,472	-	9,307	2,810	106	619	252	176	121	145	183	312	114	388
Buy Backs	4.6%	83.00	79.00	192	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CELZ Income Statement

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 0
Cost of revenues	0	0
Gross profit	0	0
OPERATING EXPENSES
Research and development	422,392	319,029
Selling, general and administrative	671,484	771,020
Amortization of patent costs	29,271	23,021
TOTAL EXPENSES	1,123,147	1,113,070
Operating loss	(1,123,147)	(1,113,070)
OTHER INCOME/(EXPENSE)
Interest expense	0	(50)
Interest income	81,603	61,197
Total other income (expense)	81,603	61,147
LOSS BEFORE PROVISION FOR INCOME TAXES	(1,041,544)	(1,051,923)
Provision for income taxes	0	0
NET LOSS	$ (1,041,544)	$ (1,051,923)
NET LOSS PER SHARE - BASIC AND DILUTED	$ (0.73)	$ (0.75)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	1,421,439	1,407,624

CELZ Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash	$ 9,007,398	$ 3,466,867
Investments	0	6,520,191
Inventory	6,594	6,594
Prepaids and other current assets	190,564	277,246
Total Current Assets	9,204,556	10,270,898
OTHER ASSETS
Other assets	3,281	3,281
Licenses, net of amortization	411,740	441,011
TOTAL ASSETS	9,619,577	10,715,190
CURRENT LIABILITIES
Accounts payable	336,845	317,280
Accrued expenses	39,920	39,920
Advances from related party	14,194	14,194
Total Current Liabilities	390,959	371,394
TOTAL LIABILITIES	390,959	371,394
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,126 and 1,431,126 issued and 1,354,626 and 1,373,626 outstanding at March 31, 2024 and December 31, 2023, respectively	1,431	1,431
Additional paid-in capital	69,720,911	69,711,749
Accumulated deficit	(60,139,976)	(59,098,432)
Treasury stock, at cost, 76,500 and 57,500 shares as of March 31, 2024 and December 31, 2023	(353,748)	(270,952)
TOTAL STOCKHOLDERS' EQUITY	9,228,618	10,343,796
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 9,619,577	$ 10,715,190

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

CEO	Mr. Timothy Warbington
WEBSITE	creativemedicaltechnology.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Creative Medical Technology Holdings Frequently Asked Questions

What is the ticker symbol for Creative Medical Technology Holdings? What does CELZ stand for in stocks?

CELZ is the stock ticker symbol of Creative Medical Technology Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Creative Medical Technology Holdings (CELZ)?

As of Fri May 17 2024, market cap of Creative Medical Technology Holdings is 5.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELZ stock?

You can check CELZ's fair value in chart for subscribers.

What is the fair value of CELZ stock?

You can check CELZ's fair value in chart for subscribers. The fair value of Creative Medical Technology Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Creative Medical Technology Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CELZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Creative Medical Technology Holdings a good stock to buy?

The fair value guage provides a quick view whether CELZ is over valued or under valued. Whether Creative Medical Technology Holdings is cheap or expensive depends on the assumptions which impact Creative Medical Technology Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELZ.

What is Creative Medical Technology Holdings's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CELZ's PE ratio (Price to Earnings) is -1.11 and Price to Sales (PS) ratio is 55.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CELZ PE ratio will change depending on the future growth rate expectations of investors.